Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression

• Status: Completed
• Trial end date: 2009-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will use measurements of depression symptoms and brain activity to determine what factors may influence an individual's response to treatment for depression.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, Los Angeles
• Collaborators: Eli Lilly and Company; National Center for Complementary and Integrative Health (NCCIH); Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Citalopram; Dexetimide; Duloxetine Hydrochloride; Venlafaxine Hydrochloride

Criteria

Inclusion Criteria:

• Clinical diagnosis of unipolar major depression

Exclusion Criteria:

• Substance abuse

• Psychotic disorder

• History of severe head trauma